Beyond the letter of the law: the US Federal Circuit interprets section 271(g)(1)
Tsao
R
R
Hurley
E A
EA
D001709:Biotechnology / Q000331:legislation & jurisprudence*; D002433:Cefaclor; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D017239:Paclitaxel; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D011994:Recombinant Proteins; D014481:United States
D011994:Recombinant Proteins; D002433:Cefaclor; D017239:Paclitaxel